Panelists explore how clinicians differentiate among available androgen receptor pathway inhibitor (ARPI)-based doublet therapies for patients with metastatic castration-sensitive prostate cancer (mCSPC).
Gordon Brown, DO, FACOS
Advertisement
Articles by Gordon Brown, DO, FACOS
Experts unpack evolving mCSPC care, from ARPIs and chemo to PARP and PSMA advances, plus guideline-driven, personalized therapy choices.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Urology Times
1
ARASEC: Clinical Implications and the Role of Multidisciplinary Care
2
2026 AUA/SUO Advanced Prostate Cancer Guideline: Key updates and clinical FAQs
3
FDA grants tentative approval to generic enzalutamide tablets
4
Atish Choudhury, MD, PhD, highlights phase 2 data on treatment interruption in mHSPC
5